Sell4

Alamar Biosciences, Inc.

ALMR

Total Value

$10.3M

Net $10.3M sold

Filing Date

Oct 23, 2026

24 transactions

Sales

$10.3M

24 transactions

Trade Summary

On Oct 21, 2026 through Oct 22, 2026, Qiming Corporate GP VI, Ltd., Insider, sold $10.3M of Alamar Biosciences, Inc. (ALMR) across 24 transactions. The filing covers Common Stock and reflects net selling of $10.3M. Reported prices ranged from $29.00 to $30.81. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

ALMR daily price with the insider's sale marked at $29.93.

Sold in the upper half of the 6-month range · the stock trades 3% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Qiming Corporate GP VI, Ltd.
Role: Insider

Filing Details

Filing Date: Oct 23, 2026
Transaction Date: Oct 21, 2026
Accession Number: 0001231919-26-001497
Form Type: 4
Net Trading Amount: -$10.3M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 21, 2026	Common Stock	592	$29.01	Sale	$17.2K
Oct 21, 2026	Common Stock	677	$29.75	Sale	$20.1K
Oct 21, 2026	Common Stock	2,380	$30.79	Sale	$73.3K
Oct 21, 2026	Common Stock	22,020	$29.01	Sale	$638.8K
Oct 21, 2026	Common Stock	25,177	$29.75	Sale	$749.0K
Oct 21, 2026	Common Stock	88,434	$30.79	Sale	$2.7M
Oct 21, 2026	Common Stock	5,138	$29.01	Sale	$149.1K
Oct 21, 2026	Common Stock	5,875	$29.75	Sale	$174.8K
Oct 21, 2026	Common Stock	20,634	$30.79	Sale	$635.3K
Oct 21, 2026	Common Stock	6,151	$29.01	Sale	$178.4K
Oct 21, 2026	Common Stock	7,033	$29.75	Sale	$209.2K
Oct 21, 2026	Common Stock	24,704	$30.79	Sale	$760.6K
Oct 22, 2026	Common Stock	1,246	$29.00	Sale	$36.1K
Oct 22, 2026	Common Stock	994	$29.59	Sale	$29.4K
Oct 22, 2026	Common Stock	99	$30.81	Sale	$3.1K
Oct 22, 2026	Common Stock	46,290	$29.00	Sale	$1.3M
Oct 22, 2026	Common Stock	36,941	$29.59	Sale	$1.1M
Oct 22, 2026	Common Stock	3,683	$30.81	Sale	$113.5K
Oct 22, 2026	Common Stock	10,800	$29.00	Sale	$313.2K
Oct 22, 2026	Common Stock	8,620	$29.59	Sale	$255.1K
Oct 22, 2026	Common Stock	859	$30.81	Sale	$26.5K
Oct 22, 2026	Common Stock	12,931	$29.00	Sale	$375.0K
Oct 22, 2026	Common Stock	10,319	$29.59	Sale	$305.3K
Oct 22, 2026	Common Stock	1,029	$30.81	Sale	$31.7K

Want live alerts when Qiming Corporate GP VI, Ltd. trades again?

Download Insider Trades to track ALMR, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.32, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1), (3), (4), (8), (9) and (10) to this Form 4
(F2)These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $30.17, inclusive
(F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.39 to $31.11, inclusive.
(F5)These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(F6)These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(F7)These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(F8)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.355, inclusive.
(F9)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $30.33, inclusive.
(F10)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $31.23, inclusive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Qiming Corporate GP VI, Ltd.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/21/2026		S		592	D	$29.01⁽¹⁾	177,734	I	See footnote⁽²⁾
Common Stock	10/21/2026		S		677	D	$29.75⁽³⁾	177,057	I	See footnote⁽²⁾
Common Stock	10/21/2026		S		2,380	D	$30.79⁽⁴⁾	174,677	I	See footnote⁽²⁾
Common Stock	10/21/2026		S		22,020	D	$29.01⁽¹⁾	6,605,306	I	See footnote⁽⁵⁾
Common Stock	10/21/2026		S		25,177	D	$29.75⁽³⁾	6,580,129	I	See footnote⁽⁵⁾
Common Stock	10/21/2026		S		88,434	D	$30.79⁽⁴⁾	6,491,695	I	See footnote⁽⁵⁾
Common Stock	10/21/2026		S		5,138	D	$29.01⁽¹⁾	1,541,222	I	See footnote⁽⁶⁾
Common Stock	10/21/2026		S		5,875	D	$29.75⁽³⁾	1,535,347	I	See footnote⁽⁶⁾
Common Stock	10/21/2026		S		20,634	D	$30.79⁽⁴⁾	1,514,713	I	See footnote⁽⁶⁾
Common Stock	10/21/2026		S		6,151	D	$29.01⁽¹⁾	1,845,199	I	See footnote⁽⁷⁾
Common Stock	10/21/2026		S		7,033	D	$29.75⁽³⁾	1,838,166	I	See footnote⁽⁷⁾
Common Stock	10/21/2026		S		24,704	D	$30.79⁽⁴⁾	1,813,462	I	See footnote⁽⁷⁾
Common Stock	10/22/2026		S		1,246	D	$29⁽⁸⁾	173,431	I	See footnote⁽²⁾
Common Stock	10/22/2026		S		994	D	$29.59⁽⁹⁾	172,437	I	See footnote⁽²⁾
Common Stock	10/22/2026		S		99	D	$30.81⁽¹⁰⁾	172,338	I	See footnote⁽²⁾
Common Stock	10/22/2026		S		46,290	D	$29⁽⁸⁾	6,445,405	I	See footnote⁽⁵⁾
Common Stock	10/22/2026		S		36,941	D	$29.59⁽⁹⁾	6,408,464	I	See footnote⁽⁵⁾
Common Stock	10/22/2026		S		3,683	D	$30.81⁽¹⁰⁾	6,404,781	I	See footnote⁽⁵⁾
Common Stock	10/22/2026		S		10,800	D	$29⁽⁸⁾	1,503,913	I	See footnote⁽⁶⁾
Common Stock	10/22/2026		S		8,620	D	$29.59⁽⁹⁾	1,495,293	I	See footnote⁽⁶⁾
Common Stock	10/22/2026		S		859	D	$30.81⁽¹⁰⁾	1,494,434	I	See footnote⁽⁶⁾
Common Stock	10/22/2026		S		12,931	D	$29⁽⁸⁾	1,800,531	I	See footnote⁽⁷⁾
Common Stock	10/22/2026		S		10,319	D	$29.59⁽⁹⁾	1,790,212	I	See footnote⁽⁷⁾
Common Stock	10/22/2026		S		1,029	D	$30.81⁽¹⁰⁾	1,789,183	I	See footnote⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

Qiming Corporate GP VI, Ltd.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Qiming Managing Directors Fund VI, L.P.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Qiming Venture Partners VI, L.P.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Qiming GP VIII, LLC

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Qiming Venture Partners VIII Investments, LLC

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Qiming GP VIII-HC, LLC

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Qiming Venture Partners VIII-HC, L.P.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

PO BOX 309

(Street)

UGLAND HOUSE

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.32, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1), (3), (4), (8), (9) and (10) to this Form 4

2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $30.17, inclusive

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.39 to $31.11, inclusive.

5. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

6. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

7. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.355, inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $30.33, inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $31.23, inclusive.

	Qiming Corporate GP VI, Ltd By: /s/ Ho Man LAM/Authorized Signatory	10/23/2026
	Qiming Managing Directors Fund VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory	10/23/2026
	Qiming Venture Partners VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory	10/23/2026
	Qiming GP VIII, LLC By: /s/ Ho Man LAM/Authorized Signatory	10/23/2026
	Qiming Venture Partners VIII Investments, LLC By: /s/ Ho Man LAM/Manager	10/23/2026
	Qiming GP VIII-HC, LLC By: /s/ Ho Man LAM/Authorized Signatory	10/23/2026
	Qiming Venture Partners VIII-HC, L.P. By: /s/ Ho Man LAM/Authorized Signatory	10/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001231919-26-001497.

Alamar Biosciences, Inc.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when Qiming Corporate GP VI, Ltd. trades again?

Footnotes

SEC Form 4

SEC Filing

Price at the Time of the Trade

SEC Form 4